Allergan PLC. (AGN) Shares Sold by ICM Asset Management Inc. WA
ICM Asset Management Inc. WA reduced its position in shares of Allergan PLC. (NYSE:AGN) by 23.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,185 shares of the company’s stock after selling 355 shares during the period. ICM Asset Management Inc. WA’s holdings in Allergan PLC. were worth $283,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. Crestwood Advisors Group LLC purchased a new stake in shares of Allergan PLC. during the first quarter worth $103,000. Feltz Wealth PLAN Inc. purchased a new stake in shares of Allergan PLC. during the first quarter worth $107,000. Enterprise Financial Services Corp increased its stake in shares of Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock worth $110,000 after buying an additional 178 shares during the period. JNBA Financial Advisors increased its stake in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares during the period. Finally, Webster Bank N. A. increased its stake in shares of Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock worth $124,000 after buying an additional 123 shares during the period. Institutional investors and hedge funds own 84.77% of the company’s stock.
Shares of Allergan PLC. (NYSE:AGN) traded up 1.5144% on Tuesday, reaching $244.8731. The company’s stock had a trading volume of 654,894 shares. The stock has a 50-day moving average of $245.21 and a 200 day moving average of $237.12. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The stock has a market capitalization of $82.24 billion, a price-to-earnings ratio of 7.6299 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The firm had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same period last year, the firm posted $3.35 EPS. The business’s revenue was up 8.8% on a year-over-year basis. On average, analysts expect that Allergan PLC. will post $16.21 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a dividend of $0.70 per share. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.16%. Allergan PLC.’s dividend payout ratio is 9.95%.
TRADEMARK VIOLATION NOTICE: “Allergan PLC. (AGN) Shares Sold by ICM Asset Management Inc. WA” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/08/allergan-plc-agn-shares-sold-by-icm-asset-management-inc-wa.html.
AGN has been the subject of a number of research analyst reports. Royal Bank Of Canada set a $279.00 price target on Allergan PLC. and gave the company a “buy” rating in a report on Wednesday, April 12th. Mizuho lowered their price target on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. Cowen and Company set a $400.00 price target on Allergan PLC. and gave the company a “buy” rating in a report on Thursday, June 8th. UBS AG reiterated a “buy” rating and issued a $275.00 price target on shares of Allergan PLC. in a report on Monday, May 15th. Finally, Citigroup Inc. boosted their price target on Allergan PLC. to $261.00 and gave the company a “buy” rating in a report on Monday, April 24th. Seven analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Allergan PLC. presently has an average rating of “Buy” and a consensus price target of $274.14.
In related news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.36% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.